Northwest Biotherapeutics (OTCMKTS:NWBO) had its price objective decreased by S&P Equity Research from $0.28 to $0.23 in a research report sent to investors on Tuesday, May 29th.

Separately, ValuEngine raised Northwest Biotherapeutics from a strong sell rating to a sell rating in a research note on Friday, February 2nd.

Shares of OTCMKTS NWBO remained flat at $$0.26 during trading on Tuesday. The stock had a trading volume of 1,451,959 shares, compared to its average volume of 1,815,379. Northwest Biotherapeutics has a 1 year low of $0.14 and a 1 year high of $0.40. The company has a debt-to-equity ratio of -0.08, a quick ratio of 0.01 and a current ratio of 0.01.

Northwest Biotherapeutics Company Profile

Northwest Biotherapeutics, Inc, a biotechnology company, discovers and develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.

Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with's FREE daily email newsletter.